Naseem Zojwalla Sells 99,509 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider Naseem Zojwalla sold 99,509 shares of the company’s stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $27.66, for a total transaction of $2,752,418.94. Following the completion of the sale, the insider directly owned 4,488 shares in the company, valued at approximately $124,138.08. The trade was a 95.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Naseem Zojwalla also recently made the following trade(s):

• On Friday, December 19th, Naseem Zojwalla sold 70,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $28.20, for a total transaction of $1,974,000.00.
• On Monday, December 22nd, Naseem Zojwalla sold 100,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $28.04, for a total value of $2,804,000.00.

Olema Pharmaceuticals Trading Down 1.2%

OLMA stock opened at $27.34 on Thursday. Olema Pharmaceuticals, Inc. has a 1-year low of $2.86 and a 1-year high of $36.26. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $18.92 and its 200-day moving average is $10.68. The firm has a market cap of $1.88 billion, a P/E ratio of -14.62 and a beta of 1.87.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Equities analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on OLMA shares. HC Wainwright increased their target price on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Citigroup upped their price objective on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Zacks Research upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Wednesday, October 8th. Finally, The Goldman Sachs Group increased their price target on Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Olema Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.50.

Hedge Funds Weigh In On Olema Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Susquehanna International Group LLP grew its stake in shares of Olema Pharmaceuticals by 20.6% during the third quarter. Susquehanna International Group LLP now owns 112,277 shares of the company’s stock valued at $1,099,000 after purchasing an additional 19,182 shares during the last quarter. Quarry LP acquired a new position in Olema Pharmaceuticals during the 3rd quarter worth $184,000. Paradigm Biocapital Advisors LP lifted its holdings in Olema Pharmaceuticals by 0.4% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 6,794,172 shares of the company’s stock worth $66,515,000 after buying an additional 30,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Olema Pharmaceuticals in the 3rd quarter valued at $268,000. Finally, Kingdon Capital Management L.L.C. acquired a new stake in shares of Olema Pharmaceuticals in the 3rd quarter valued at $8,361,000. 91.78% of the stock is owned by institutional investors.

Key Stores Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Seeking Alpha reiterates a “Strong Buy” on Olema driven by initiation of the OPERA‑02 pivotal trial and promising combo data (palazestrant + KISQALI), highlighting OPERA‑01 readout in 2H‑2026 and OPERA‑02 topline in 2028 as key value catalysts. Seeking Alpha – Strong Buy on OPERA‑02
• Positive Sentiment: Several sell‑side firms have raised targets and reiterated buys (Goldman, Citi, JPMorgan, UBS), lifting the consensus price target (~$40.50 average), which supports upside if clinical milestones land.
• Neutral Sentiment: Reported short interest data shows effectively zero shares short and a 0.0 days‑to‑cover figure, indicating short sellers are not currently positioned to amplify moves (data appears to show no measurable short interest for December).
• Negative Sentiment: Director Ian T. Clark sold 264,800 shares on Dec. 19 at ~$29.73 (≈$7.87M), a large director‑level disposal that can raise governance/lockup concern and pressure the stock. SEC Form 4 – Clark sale 12/19/2025
• Negative Sentiment: Naseem Zojwalla executed multiple large sales (100,000; 70,000; 99,509 shares across Dec. 19–23), reducing his stake materially and generating roughly $7.5M+ in proceeds across those trades. SEC Form 4 – Zojwalla sales
• Negative Sentiment: David C. Myles sold 51,000 shares on Dec. 19 at ~$30.46 (~$1.55M), trimming his holding by ~8.5%—another insider sale contributing to near‑term selling pressure. SEC Form 4 – Myles sale 12/19/2025

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.